Answers are grounded in this paper and cite their sources.
Background Ovarian cancer is typically diagnosed at an advanced stage with peritoneal metastases and remains associated with high relapse rates and limited therapeutic options. While chimeric antigen receptor (CAR)-based immunotherapies have demonstrated remarkable success in hematologic malignancies, their implementation against solid tumors remains challenging due to tumor heterogeneity and an immunosuppressive microenvironment. Mesothelin, a cell-surface glycoprotein overexpressed in ovarian cancer and largely absent in healthy tissues, represents a promising therapeutic target. Material and methods Third-generation anti-Mesothelin CAR constructs containing CD28, 4-1BB, and CD3ζ signaling domains were introduced into NK-92 cells using self-inactivating (SIN) alpharetroviral or lentiviral vectors. CAR expression, vector copy numbers, and cytotoxic activity were evaluated in 2D and 3D co-culture models employing ovarian cancer cell lines (OVCAR3, A2780) and primary patient-derived tumor cells. Cytotoxicity was assessed through live-cell imaging and flow cytometry. Results Mesothelin was highly expressed in ovarian cancer cell lines and patient tumor samples, but minimally detected in healthy ovarian tissues. Alpharetroviral anti-Mesothelin CAR-NK-92 cells exhibited potent, antigen-dependent cytotoxicity against Mesothelin-high OVCAR3 and primary ovarian cancer cells in 2D models and pronounced tumor reduction in 3D spheroid assays. Additionally, alpharetroviral CAR-NK-92 cells demonstrated greater cytotoxic activity compared to lentiviral counterparts. Conclusion Our findings demonstrate significant antitumor activity of alpharetroviral anti-Mesothelin CAR-NK-92 cells in vitro, underscoring Mesothelin as a promising therapeutic target in ovarian cancer. The favorable safety profile and high performance of alpharetroviral vectors support their further development as a platform for next-generation CAR-NK cell therapies against solid malignancies.
No takes yet. Share an insight, caveat, or question.
Stalp et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: